Company: INDP
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001641172-25-006429
Chunk: 65

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 65
---
 2025.                                       |

| (12) | Consists                                                                                  
 of 182,000 shares of common stock issuable upon exercise of outstanding options, of which 
 30,000 will vest within 60 days of April 17, 2025.                                        |

| (13) | Consists                                                                                 
 of 58,750 shares of common stock issuable upon exercise of outstanding options, of which 
 12,500 will vest within 60 days of April 17, 2025.                                       |

| (14) | Consists                                                                                 
 of 32,500 shares of common stock issuable upon exercise of outstanding options, of which 
 12,500 will vest within 60 days of April 17, 2025.                                       |

| (15) | Consists                                                                                   
 of (i) 1,572,035 shares of common stock, (ii) 127,485 shares of common stock issuable upon 
 exercise of warrants, and (ii) 2,048,742 shares of common stock issuable upon exercise of  
 outstanding options, of which 146,375 will vest within 60 days of days of April 17, 2025.  |

Delinquent Section 16(a) Reports

Section 16(a) of the Exchange Act requires our executive officers and directors and persons who beneficially own more than 10% of our common stock to file with the SEC reports of their ownership and changes in their ownership of our common stock. To our knowledge, based solely on review of the copies of such reports and amendments to such reports with respect to the year ended December 31, 2024 filed with the SEC and on written representations by our directors and executive officers, all required Section 16 reports under the Exchange Act for our directors, executive officers and beneficial owners of greater than 10% of our common stock were filed on a timely basis during the year ended December 31, 2024.

| 41 |

<div align='center'>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</div>

Policies and Procedures for Related Person Transactions

In accordance with our audit committee charter, the Audit Committee is required to approve related party transactions. In general, the Audit Committee will review any proposed transaction that has been identified as a related person transaction under Item 404 of Regulation S-K, which means a transaction, arrangement or relationship in which we and any related person (as defined below) are participants in which the amount involved exceeds the lesser of